Sign in to continue:

Wednesday, March 4th, 2026

Anteris Technologies Global Corp. 8-K SEC Filing Details: Company Information, Stock, and XBRL Data




Anteris Technologies Global Corp. 8-K Filing: Key Investor Insights

Anteris Technologies Global Corp. (AVR) Files Form 8-K: Key Details for Investors

Executive Summary

Anteris Technologies Global Corp. (NASDAQ: AVR), a company specializing in orthopedic, prosthetic, and surgical appliances, filed a Form 8-K with the U.S. Securities and Exchange Commission on March 3, 2026. The report covers key corporate events as of February 26, 2026. This filing includes information that is crucial for shareholders and may impact the company’s valuation and share price.

Key Points from the 8-K Filing

  • Corporate Event: The filing primarily addresses the “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.”
  • Emerging Growth Company Status: Anteris Technologies Global Corp. is classified as an “Emerging Growth Company” under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934.
  • Securities Registered: The company’s common stock (par value \$0.0001 per share) is traded on the Nasdaq Global Market under the symbol AVR.
  • Business and Contact Information:
    • Business Address: 860 Blue Gentian Road, Suite 340, Eagan, MN 55121
    • Telephone (Australia): +61 7 3152 3200
  • Filing Details:
    • SEC File Number: 001-42437
    • Tax Identification Number (EIN): 99-1407174
    • State of Incorporation: Delaware (DE)
    • Date of Report: February 26, 2026
    • Fiscal Year End: December 31
  • CEO Signature: The filing is signed by Wayne Paterson, Vice Chairman and Chief Executive Officer, confirming its authenticity and relevance.

Important Shareholder Information & Potential Price Sensitivity

  • Departure/Election/Appointment of Key Officers:
    The 8-K specifically covers changes in the company’s leadership, which could signal strategic shifts, impact ongoing projects, or affect investor confidence. The departure, election, or appointment of directors and key officers is often viewed as a price-sensitive event by the market, especially if the individuals involved are considered crucial to the company’s performance or future direction.
  • Compensatory Arrangements:
    The filing indicates updates to compensatory arrangements for certain officers. Any changes in executive compensation, especially for CEOs or other senior management, can have implications for shareholder value, governance practices, and market perception.
  • Emerging Growth Company Implications:
    As an emerging growth company, Anteris Technologies may benefit from reduced regulatory burdens and extended transition periods for new accounting standards. This status can affect the company’s financial reporting, governance, and investment profile.
  • No Pre-commencement Communications:
    The company confirms it has not engaged in written communications, soliciting material, or pre-commencement tender offers under relevant SEC rules, indicating no current plans for mergers, acquisitions, or significant corporate actions that would require such disclosures.

Details of Securities and Trading Information

Title of Security Trading Symbol Exchange
Common Stock, par value \$0.0001 per share AVR NASDAQ Global Market

Summary of Regulatory Status

  • Anteris Technologies is not amending any previously filed or accepted submission (Amendment Flag: false).
  • No indication of extended transition period for new accounting standards (Entity Ex Transition Period: false).
  • All required boxes for written communications, soliciting material, pre-commencement tender offers, and issuer tender offers are marked false.

Potential Impact on Share Price

The departure, election, or appointment of directors or officers as well as changes to compensatory arrangements are typically viewed as material events by investors. These could lead to increased volatility depending on the market’s perception of the individuals involved and their influence on company strategy. The company’s status as an emerging growth company may also affect investor sentiment, particularly those interested in high-growth, early-stage opportunities.

Conclusion

Investors should closely monitor further disclosures from Anteris Technologies Global Corp. regarding the details of officer departures, elections, appointments, and compensation changes. Such events can significantly affect management stability, corporate strategy, and ultimately share price.


Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors are advised to consult professional advisers and review official SEC filings for complete information. The author does not hold any position in Anteris Technologies Global Corp. and is not compensated by the company. All information is sourced from official SEC filings and is believed to be accurate at the time of publication, but accuracy is not guaranteed.




View Anteris Technologies Global Corp. Historical chart here



Biohaven Ltd. 2025 Annual Report: Key Programs, Clinical Pipeline, and Strategic Focus in Neuroscience and Metabolic Diseases

Biohaven Ltd. 2025 Annual Report: Key Highlights and Investor Insights Overview Biohaven Ltd., a biopharmaceutical company headquartered in New Haven, CT, has released its Annual Report on Form 10-K for the fiscal year ended...

Goldman Sachs BDC, Inc. 8-K Filing Summary for February 25, 2026 – Company Details, Exchange Information, and Executive Signatures 23567151617

Goldman Sachs BDC, Inc. Announces Board Changes and Director Reclassifications Key Highlights: The Board of Directors of Goldman Sachs BDC, Inc. (“GSBD” or the “Company”) has reduced its size from seven to six directors...

Evolus Reports Q4 & Full-Year 2025 Results: Sixth Year of Double-Digit Growth, 2026 Profitability Outlook, and Strong Revenue Guidance

Evolus, Inc. Reports Q4 and Full-Year 2025 Financial Results: Key Details for Investors Evolus, Inc. (NASDAQ: EOLS) Reports Q4 and Full-Year 2025 Financial Results: Sixth Consecutive Year of Double-Digit Growth, Sustainable Profitability Expected in...

   Ad